QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Board declares interim dividend of Rs 2 per equity share
Subscribe To Our Newsletter & Stay Updated
